ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer
July 18, 2023 07:00 ET
|
Acelyrin, Inc.
Accomplished global leader brings 20 years of immunology sales and marketing expertise. ACEYLRIN currently has a robust portfolio including late-stage clinical trials underway supporting multiple...
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
June 15, 2023 16:05 ET
|
Acelyrin, Inc.
Initial Public Offering generated gross proceeds of $621 million; net proceeds of $573.7 million– Strong cash position of $289.2 million at end of Q1 2023– $862.9 million from IPO net proceeds and...